Skip to menu Skip to content Skip to footer

2024

Journal Article

Epstein–Barr virus‐associated lymphomas decoded

Bednarska, Karolina, Chowdhury, Rakin, Tobin, Joshua W. D., Swain, Fiona, Keane, Colm, Boyle, Stephen, Khanna, Rajiv and Gandhi, Maher K. (2024). Epstein–Barr virus‐associated lymphomas decoded. British Journal of Haematology, 204 (2), 415-433. doi: 10.1111/bjh.19255

Epstein–Barr virus‐associated lymphomas decoded

2024

Journal Article

EBNA2: a viral maestra conducting a symphony orchestra

Gandhi, Maher K. and Kelly, Gemma L. (2024). EBNA2: a viral maestra conducting a symphony orchestra. Blood, 143 (5), 384-385. doi: 10.1182/blood.2023022744

EBNA2: a viral maestra conducting a symphony orchestra

2024

Journal Article

EBV-infected hematopoietic stem cells drive CAEBV

Khanna, Rajiv and Gandhi, Maher K. (2024). EBV-infected hematopoietic stem cells drive CAEBV. Blood, 143 (1), 2-4. doi: 10.1182/blood.2023022739

EBV-infected hematopoietic stem cells drive CAEBV

2024

Journal Article

The IRE1α endonuclease plays a dual role in regulating the XBP1/miRNA-34a axis and PD-1 Expression within natural killer cells in Hodgkin lymphoma

Bednarska, Karolina, Thillaiyampalam, Gayathri, Mujaj, Sally, Nourse, Jamie, Gunawardana, Jay, Sabdia, Muhammed B., Law, Soi C., Pilaar, Anna, Cui, Qingyan, de Long, Lilia M., Vari, Frank, Gandhi, Maher K. and Cristino, Alexandre S. (2024). The IRE1α endonuclease plays a dual role in regulating the XBP1/miRNA-34a axis and PD-1 Expression within natural killer cells in Hodgkin lymphoma. Acta Haematologica, 147 (6), 1-16. doi: 10.1159/000536044

The IRE1α endonuclease plays a dual role in regulating the XBP1/miRNA-34a axis and PD-1 Expression within natural killer cells in Hodgkin lymphoma

2023

Conference Publication

High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL

Sabdia, Muhammed B., Burgess, Melinda, Law, Soi Cheng, Thurgood, Lauren A., Kazakoff, Stephen, Swain, Fiona, Tobin, Joshua W.D., Mollee, Peter, Patch, Ann-Marie and Gandhi, Maher K (2023). High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-174149

High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL

2023

Journal Article

Genome-wide transcription factor binding maps reveal cell-specific changes in the regulatory architecture of human HSPC

Subramanian, Shruthi, Thoms, Julie A I, Huang, Yizhou, Cornejo Paramo, Carina Paola, Koch, Forrest Charles, Jacquelin, Sebastien, Shen, Sylvie, Song, Emma, Joshi, Swapna, Brownlee, Christopher Peter, Woll, Petter S., Chacon-Fajardo, Diego, Beck, Dominik, Curtis, David J, Yehson, Kenneth, Antonenas, Vicki, O'Brien, Tracey, Trickett, Annette, Powell, Jason A., Lewis, Ian D, Pitson, Stuart M, Gandhi, Maher K., Lane, Steven W, Vafaee, Fatemeh, Wong, Emily, Gottgens, Berthold, Rokny, Hamid, Wong, Jason Wing Hon and Pimanda, John E (2023). Genome-wide transcription factor binding maps reveal cell-specific changes in the regulatory architecture of human HSPC. Blood Journal, 142 (17), 1448-1462. doi: 10.1182/blood.2023021120

Genome-wide transcription factor binding maps reveal cell-specific changes in the regulatory architecture of human HSPC

2023

Journal Article

Regulatory T cells hamper the efficacy of T-cell engaging bispecific antibody therapy

Casey, Mika, Lee, Carol, Kwok, Wing Yu, Law, Soi Cheng, Corvino, Dillon, Gandhi, Maher K., Harrison, Simon J. and Nakamura, Kyohei (2023). Regulatory T cells hamper the efficacy of T-cell engaging bispecific antibody therapy. Haematologica, 109 (3), 787-798. doi: 10.3324/haematol.2023.283758

Regulatory T cells hamper the efficacy of T-cell engaging bispecific antibody therapy

2023

Conference Publication

Final Analysis Of Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study Of Ibrutinib, Rituximab And Mini-chop In Very Elderly Patients With Newly Diagnosed DLBCL

Verner, Emma, Johnston, Amanda, Pati, Nalini, Hawkes, Eliza, Peng Lee, Hui, Cochrane, Tara, Yoon Cheah, Chan, Filshie, Robin, Purtill, Duncan, Sia, Hanlon, Enjeti, Anoop K, Brown, Christina, Murphy, Nicholas, Curnow, Jennifer, Lee, Kenneth, Gandhi, Maher, Butcher, Belinda and Trotman, Judith (2023). Final Analysis Of Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study Of Ibrutinib, Rituximab And Mini-chop In Very Elderly Patients With Newly Diagnosed DLBCL. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971404.12997.4b

Final Analysis Of Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study Of Ibrutinib, Rituximab And Mini-chop In Very Elderly Patients With Newly Diagnosed DLBCL

2023

Journal Article

Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma

Gandhi, Maher K. and Keane, Colm (2023). Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma. Haematologica, 108 (12), 3195-3196. doi: 10.3324/haematol.2023.283392

Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma

2023

Conference Publication

Rituximab‐containing combined modality therapy in limited stage follicular lymphoma: mature follow up and derivation of a novel prognostic score from the TROG99.03 trial

Tobin, J. W., Jurinovic, V., Tsang, H., Roos, D., Tsang, R., Macann, A., Davis, S., Christie, D., Law, S., Nath, K., Sabdia, M., Patch, A. M., Gunawardana, J., Merida de Long, L., Hoster, E., Horn, H., Shanavas, M., Li, L., Cheah, C., Benhur, A., Hou, M., O'Brien, P., Johnston, A. M., Cochrane, T., Butler, J., Thompson, E., Blombery, P., Seymour, J. F., Gandhi, M. K. and MacManus, M. (2023). Rituximab‐containing combined modality therapy in limited stage follicular lymphoma: mature follow up and derivation of a novel prognostic score from the TROG99.03 trial. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13-17 June 2023. Oxford, United Kingdom: John Wiley & Sons. doi: 10.1002/hon.3163_140

Rituximab‐containing combined modality therapy in limited stage follicular lymphoma: mature follow up and derivation of a novel prognostic score from the TROG99.03 trial

2023

Conference Publication

Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse

Swain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., Talaulikar, D., Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M. K. and Keane, C. (2023). Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_191

Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse

2023

Conference Publication

Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL

Verner, E., Johnston, A., Pati, N., Hawkes, E., Lee, H. P., Cochrane, T., Cheah, C. Y., Filshie, R., Purtill, D., Sia, H., Enjeti, A. K., Brown, C., Murphy, N., Curnow, J., Lee, K., Gandhi, M. K., Butcher, B. E. and Trotman, J. (2023). Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_313

Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL

2023

Conference Publication

Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma

Tobin, J. W., Tsang, H., Patch, A., Keane, C., Law, S. C., Gunawardana, J., Blombery, P., Thompson, E. R., Sabdia, M. B., De Long, L. M., Nath, K., Kazakoff, S. H., Cheah, C., Amanuel, B., Cochrane, T., Butler, J., Johnston, A., Shanavas, M., Li, L., Shelton, V., Hershenfeld, S., Kridel, R., Seymour, J. F., MacManus, M. and Gandhi, M. K. (2023). Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_189

Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma

2023

Journal Article

Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia

Burgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631

Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia

2023

Journal Article

A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma

George, Hannah, Gunawardana, Jay, Keane, Colm, Hicks, Rod J. and Gandhi, Maher K. (2023). A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma. Internal Medicine Journal, 53 (7), 1105-1109. doi: 10.1111/imj.16078

A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma

2023

Journal Article

Genetic susceptibility to EBV-related disease

Gandhi, Maher K. (2023). Genetic susceptibility to EBV-related disease. Blood, 141 (13), 1499-1500. doi: 10.1182/blood.2022019180

Genetic susceptibility to EBV-related disease

2023

Journal Article

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Agrawal, Prashasti, David, Kevin A., Chen, Zhengming, Sundaram, Suchitra, Kim, Seo-Hyun, Vaca, Ryan, Lin, Yong, Singer, Samuel, Malecek, Mary-Kate, Carter, Jordan, Zayac, Adam, Kim, Myung Sun, Reddy, Nishitha, Ney, Douglas, Habib, Alma, Strouse, Christopher, Graber, Jerome, Bachanova, Veronika, Salman, Sidra, Vendiola, Jean A., Hossain, Nasheed, Tsang, Mazie, Major, Ajay, Gandhi, Maher K., Keane, Colm, Bond, David A., Folstad, Matthew, Chang, Julie, Mier-Hicks, Angel ... Martin, Peter (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia and Lymphoma, 64 (5), 1026-1034. doi: 10.1080/10428194.2023.2191152

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

2023

Journal Article

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Trotman, Judith, Presgrave, Peter, Carradice, Duncan P., Lenton, Douglas Stuart, Gandhi, Maher K., Cochrane, Tara, Badoux, Xavier, Carlson, Julia, Nkhoma, Gloria, Butcher, Belinda, Nikpour, Armin, Fulham, Michael and Johnston, Anna M. (2023). Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. HemaSphere, 7 (3), e836. doi: 10.1097/HS9.0000000000000836

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

2023

Journal Article

Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma

Casey, Mika, Segawa, Kane, Law, Soi Cheng, Sabdia, Muhamamed Bilal, Nowlan, Bianca, Salik, Basit, Lee, Carol, Winterford, Clay, Pearson, Sally, Madore, Jason, Dougall, William C., Gandhi, Maher K. and Nakamura, Kyohei (2023). Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Leukemia, 37 (2), 379-387. doi: 10.1038/s41375-022-01794-9

Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma

2023

Conference Publication

ANALYSIS OF THE GENETIC LANDSCAPE IN ELDERLY DIFFUSE LARGE B CELL LYMPHOMA AGED ≥ 75 YEARS IDENTIFIES NEW TARGETABLE MUTATIONS

Rijal, Sewa, Lim, Jun Hee, Smyth, Lillian, Coombes, Caitlin, Jain, Sanjiv, Saxena, Kartik, Trotman, Judith, Verner, Emma, Gandhi, Maher K., Gandhi, Kaushal and Talaulikar, Dipti (2023). ANALYSIS OF THE GENETIC LANDSCAPE IN ELDERLY DIFFUSE LARGE B CELL LYMPHOMA AGED ≥ 75 YEARS IDENTIFIES NEW TARGETABLE MUTATIONS. HOBOKEN: WILEY.

ANALYSIS OF THE GENETIC LANDSCAPE IN ELDERLY DIFFUSE LARGE B CELL LYMPHOMA AGED ≥ 75 YEARS IDENTIFIES NEW TARGETABLE MUTATIONS